Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

A view of the logo of British pharmaceutical giant GlaxoSmithKline (GSK) at the company's offices in Munich. British pharmaceutical company GSK reported on 30 October that its third-quarter profit ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

Understanding those ingredients, will impart you the essentials of the pharmaceutical market in Egypt. GSK has understood the game of access in Egypt earlier than other companies. By buying two ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...